Cargando…

BCL6 Rearrangement Indicates Poor Prognosis in Diffuse Large B-cell Lymphoma Patients: A Meta-analysis of Cohort Studies

BCL6 (3q27) rearrangement is the most frequent chromosomal abnormality in diffuse large B-cell lymphoma (DLBCL). Previously, studies on the association between BCL6 rearrangement and DLBCL outcome remain controversial. Here we systematically reviewed literatures to identify the prognostic significan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shu, Wang, Zhan, Lin, Liming, Wu, Zhaoxing, Yu, Qingfeng, Gao, Feiqiong, Zhang, Jiawei, Xu, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360306/ https://www.ncbi.nlm.nih.gov/pubmed/30719149 http://dx.doi.org/10.7150/jca.25732

Ejemplares similares

Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma with MYC-Rearrangement, and Diffuse Large B-Cell Lymphoma with MYC-Cluster Amplification
por: Miyaoka, Masashi, et al.
Publicado: (2022)

CD56-positive diffuse large B-cell lymphoma/leukemia with BCL6/MYC double-hit and multiple gene mutations: an indicator of poor prognosis?
por: Liu, Yanquan, et al.
Publicado: (2020)

High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan
por: Tsai, Cheng-Chih, et al.
Publicado: (2021)

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma
por: Ye, Qing, et al.
Publicado: (2015)

MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B‐cell lymphoma
por: Kawamoto, Keisuke, et al.
Publicado: (2016)

Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients
por: Wang, Zhitao, et al.
Publicado: (2021)

Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements
por: Frauenfeld, Leonie, et al.
Publicado: (2022)

CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma
por: Shen, Mingfang, et al.
Publicado: (2023)

TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment
por: Singh, Aditi, et al.
Publicado: (2022)

Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma
por: Zhang, YunXiang, et al.
Publicado: (2019)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
por: Okada, Yosuke, et al.
Publicado: (2021)

Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas
por: Willenbacher, Ella, et al.
Publicado: (2020)

Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection
por: Tsai, Yu-Fen, et al.
Publicado: (2021)

P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMENTS IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA FROM THE POLARIX TRIAL
por: Morschhauser, F., et al.
Publicado: (2022)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma
por: Taskinen, Minna, et al.
Publicado: (2014)

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

Cyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge
por: Gao, Da, et al.
Publicado: (2019)

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
por: Barouqa, Mohammad, et al.
Publicado: (2022)

High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression
Publicado: (2016)

High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression
por: Maura, F, et al.
Publicado: (2017)

Biallelic BCL6 rearrangements by dual t(3;14)(q27;q32) and t(3;22)(q27;q11) translocations in diffuse large B-cell lymphoma
por: Nakamura, Yuichi, et al.
Publicado: (2022)

The distinct clinical features and prognosis of the CD10(+)MUM1(+) and CD10(−)Bcl6(−)MUM1(−) diffuse large B-cell lymphoma
por: Lu, Ting-Xun, et al.
Publicado: (2016)

MYC Gene Rearrangements Are Closely Associated with Poor Survival of Diffuse Large B Cell Lymphoma with Hepatitis B Virus Infection
por: Liu, Zhihe, et al.
Publicado: (2017)

Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients
por: Manfroi, B., et al.
Publicado: (2018)

Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing
por: Künstner, Axel, et al.
Publicado: (2021)

Bcl-6-dependent risk stratification by nuclear expression of Peli1 in diffuse large B-cell lymphoma
por: Lee, Ki Rim, et al.
Publicado: (2022)

BCL-1 Gene Rearrangements in Iranian Non-Hodgkin Lymphoma Patients
por: Tohidirad, Manoush, et al.
Publicado: (2016)

Prognostic Value of Peripheral Blood Lymphocyte/monocyte Ratio in Lymphoma
por: Gao, Feiqiong, et al.
Publicado: (2021)

R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with MYC rearrangement or double expression of MYC and BCL-2
por: Sun, Peng, et al.
Publicado: (2021)

MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
por: Yan, Li-Xu, et al.
Publicado: (2014)

Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
por: Mitobe, Masaki, et al.
Publicado: (2018)

Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma
por: You, Hua, et al.
Publicado: (2021)

High PTX3 expression is associated with a poor prognosis in diffuse large B‐cell lymphoma
por: Carreras, Joaquim, et al.
Publicado: (2021)

Long noncoding RNA PVT1 promotes tumor growth and predicts poor prognosis in patients with diffuse large B‐cell lymphoma
por: Yang, Ruifeng, et al.
Publicado: (2020)

Detection of bcl-2/JH rearrangement in follicular and diffuse lymphoma: concordant results of peripheral blood and bone marrow analysis at diagnosis.
por: Yuan, R., et al.
Publicado: (1993)

MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma
por: Ying, Carol Y., et al.
Publicado: (2013)

High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation
por: Carreras, Joaquim, et al.
Publicado: (2019)

Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin
por: Wawire, Jonathan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_to3t4hf6omhkpj88p18mls0lkr